Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Gill

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Journal of Pediatric Hematology/Oncology|April 25, 2000
Low-molecular-weight heparin in thrombotic disease in children and adolescentsR C Punzalan, C A Hillery, R R Montgomery, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 9, 2011
Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008)E J Neufeld, C M Kessler, J C Gill, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 14, 2004
Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P)A R Thompson, J C Gill, B M Ewenstein, et al.
Nephron|January 1, 1994
Increased incidence of HLA-B40 group antigens in children with hemolytic-uremic syndromeK J Sheth, J C Gill, H E Leichter, et al.
Blood|June 1, 1987
The effect of ABO blood group on the diagnosis of von Willebrand diseaseJ C Gill, J Endres-Brooks, P J Bauer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 4, 2011
von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand diseaseJ C Gill, A Shapiro, L A Valentino, et al.
Blood|October 1, 1996
Type 2M:Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to plateletsD J Mancuso, P A Kroner, P A Christopherson, et al.
The Journal of Pediatrics|June 8, 2001
Bleeding disorders: A common cause of menorrhagia in adolescentsJ A Bevan, K W Maloney, C A Hillery, et al.
Thrombosis and Haemostasis|June 24, 1985
Persistence and progression of immunologic abnormalities in haemophiliaJ C Gill, D Wheeler, J E Menitove, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 30, 2018
Risk factors associated with invasive orthopaedic interventions in males with haemophilia enrolled in the Universal Data Collection program from 2000 to 2010P Tobase, H Lane, A-E-A Siddiqi, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Journal of Pediatric Hematology/Oncology|April 25, 2000
Low-molecular-weight heparin in thrombotic disease in children and adolescentsR C Punzalan, C A Hillery, R R Montgomery, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 9, 2011
Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008)E J Neufeld, C M Kessler, J C Gill, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 14, 2004
Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P)A R Thompson, J C Gill, B M Ewenstein, et al.
Nephron|January 1, 1994
Increased incidence of HLA-B40 group antigens in children with hemolytic-uremic syndromeK J Sheth, J C Gill, H E Leichter, et al.
Blood|June 1, 1987
The effect of ABO blood group on the diagnosis of von Willebrand diseaseJ C Gill, J Endres-Brooks, P J Bauer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 4, 2011
von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand diseaseJ C Gill, A Shapiro, L A Valentino, et al.
Blood|October 1, 1996
Type 2M:Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to plateletsD J Mancuso, P A Kroner, P A Christopherson, et al.
The Journal of Pediatrics|June 8, 2001
Bleeding disorders: A common cause of menorrhagia in adolescentsJ A Bevan, K W Maloney, C A Hillery, et al.
Thrombosis and Haemostasis|June 24, 1985
Persistence and progression of immunologic abnormalities in haemophiliaJ C Gill, D Wheeler, J E Menitove, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 30, 2018
Risk factors associated with invasive orthopaedic interventions in males with haemophilia enrolled in the Universal Data Collection program from 2000 to 2010P Tobase, H Lane, A-E-A Siddiqi, et al.
Pageof 8